Literature DB >> 10894958

Patient compliance and disease management in the treatment of psoriasis in the Netherlands.

P C van de Kerkhof1, D de Hoop, J de Korte, S A Cobelens, M V Kuipers.   

Abstract

BACKGROUND: Compliance behaviour and disease management are important issues in chronic skin diseases. Psoriasis patients are 'experts by experience' because of many years of treatment. Therefore, it is relevant to gather data from patients on the actual use of antipsoriatic treatments.
OBJECTIVE: The following questions are addressed: (1) What is the present mode of prescription and actual use of antipsoriatic treatments, including topical treatments, photo(chemo)therapy and systemic treatments? (2) What information do patients expect from their doctor, and do they actually receive this information.
METHODS: To answer these questions, a questionnaire survey was mailed to the subscribers of Psoriasis, the journal of the Dutch Psoriasis Patients' Organisation.
RESULTS: (1) Major issues in the treatment of psoriasis are (a) long-term management, (b) control of mild, moderate but also extensive psoriasis and (c) control of psoriasis on difficult localisations. Patients perceive itch, scaliness and visibility as major criteria for efficacy. (2) Topical treatment is the mainstay in the management of psoriasis. Calcipotriol is the most prescribed drug. Photo(chemo)therapy has an intermediate position between topical and systemic treatments. UVB is prescribed more than twice as frequently as PUVA and 10% of the patients on photo(chemo)therapy proved to be treated with UVB at home. Only 16% of the patients were on a systemic treatment; methotrexate and acitretin were the most frequently used systemic treatments. (3) More than 70% of the patients indicated that they had taken part in the selection of a treatment. In general, the patients were satisfied about the contact with their dermatologist and general practitioner. Compliance with the duration of treatment is limited, especially with regard to topical treatment. Patient compliance with the dose of the treatment is better. Again compliance is the worst in topical treatments. (4) Patients have a strong preference for an effective treatment which is safe for long-term use. Only a minority of patients wants a fast clearing treatment.
CONCLUSION: Itch, scaliness and visibility provide the most relevant information on the severity of psoriasis, as the patients perceive themselves. Treatment duration is often unrestricted, especially with regard to topical treatments, which implies that the cumulative toxicity potential of these treatments may have a serious impact on their safety profile. Patients regard it of importance to have a vote in the selection of the treatment and regard safety as more important than fast clearing. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2000        PMID: 10894958     DOI: 10.1159/000018390

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  21 in total

Review 1.  [Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review].

Authors:  M A Radtke; K Herberger; T Kornek; M Augustin
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

Review 2.  [Combined topical therapy of psoriasis: position of calcitriol and vitamin D analogs].

Authors:  J Schmitt; M Meurer
Journal:  Hautarzt       Date:  2006-08       Impact factor: 0.751

3.  A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis.

Authors:  T A Luger; F Cambazard; F G Larsen; M Bourcier; G Gupta; F Clonier; P Kidson; N H Shear
Journal:  Dermatology       Date:  2008-09-12       Impact factor: 5.366

Review 4.  Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients.

Authors:  Teo Soleymani; Soumya M Reddy; Jeffrey M Cohen; Andrea L Neimann
Journal:  Curr Rheumatol Rep       Date:  2017-11-20       Impact factor: 4.592

5.  Eliciting preferences to inform patient-centred policies: the case of psoriasis.

Authors:  Aleksandra Torbica; Giovanni Fattore; Fabio Ayala
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

Review 6.  Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.

Authors:  Gil Yosipovitch; Mark B Y Tang
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

7.  [Therapeutic benefits in dermatological therapy. Evaluation of therapy from the physician's und patient's perspective in psoriasis and atopic dermatitis].

Authors:  I Zschocke; U Hammelmann; M Augustin
Journal:  Hautarzt       Date:  2005-09       Impact factor: 0.751

8.  The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups.

Authors:  Denise Globe; Martha S Bayliss; David J Harrison
Journal:  Health Qual Life Outcomes       Date:  2009-07-06       Impact factor: 3.186

9.  Potential role of ustekinumab in the treatment of chronic plaque psoriasis.

Authors:  Santo Raffaele Mercuri; Luigi Naldi
Journal:  Biologics       Date:  2010-05-25

10.  Developing a diagnostic checklist of traditional Chinese medicine symptoms and signs for psoriasis: a Delphi study.

Authors:  Xuesong Yang; Virasakdi Chongsuvivatwong; Edward McNeil; Jianzhou Ye; Xiaoyong Ouyang; Enpin Yang; Hutcha Sriplung
Journal:  Chin Med       Date:  2013-05-12       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.